ScholarLens Back to search
2020•Leukemia & lymphoma/Leukemia and lymphomaRequires access

Mantle cell lymphoma turned SOX11 negative after ibrutinib: a report of two cases

Toshiki Terao, Kentaro Narita, Takafumi Tsushima, Daisuke Miura, Masami Takeuchi, Kosei Matsue

Open publisher page 0 citations

Abstract

Mantle cell lymphoma (MCL) comprises about 3% of all newly diagnosed non-Hodgkin’s lymphoma cases and is thought to be incurable with conventional chemotherapy [1]. Ibrutinib, approved in Japan in ...

About this research paper

What this paper is about

Mantle cell lymphoma (MCL) comprises about 3% of all newly diagnosed non-Hodgkin’s lymphoma cases and is thought to be incurable with conventional chemotherapy [1]. Ibrutinib, approved in Japan in ...

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Mantle cell lymphoma (MCL) comprises about 3% of all newly diagnosed non-Hodgkin’s lymphoma cases and is thought to be incurable with conventional chemotherapy [1]. Ibrutinib, approved in Japan in ...

Key concepts: Ibrutinib, Mantle cell lymphoma, Lymphoma, Cancer research, Medicine, Oncology, Mantle (geology), Chemotherapy

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
Mantle cell lymphoma turned SOX11 negative after ibrutinib: a report of two cases — Research Paper | ScholarLens